Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001)
2004 ◽
Vol 22
(14_suppl)
◽
pp. 3074-3074
2004 ◽
Vol 22
(14_suppl)
◽
pp. 3074-3074
◽
2019 ◽
2006 ◽
Vol 282
(5)
◽
pp. 2840-2850
◽
2005 ◽
Vol 11
(19)
◽
pp. 7080s-7086s
◽
2001 ◽
Vol 94
(6)
◽
pp. 774-782
◽